WallStSmart

Medline Inc. Class A Common Stock (MDLN)vsMarvell Technology Group Ltd (MRVL)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medline Inc. Class A Common Stock generates 234% more annual revenue ($29.14B vs $8.72B). MRVL leads profitability with a 29.0% profit margin vs 3.3%. MDLN trades at a lower P/E of 31.4x. MRVL earns a higher WallStSmart Score of 55/100 (C).

MDLN

Buy

55

out of 100

Grade: C-

Growth: 7.3Profit: 5.5Value: 4.7Quality: 6.5
Piotroski: 4/9Altman Z: 1.79

MRVL

Buy

55

out of 100

Grade: C

Growth: 6.0Profit: 7.0Value: 3.7Quality: 8.0
Piotroski: 5/9Altman Z: 1.90

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDLN2 strengths · Avg: 9.0/10
EPS GrowthGrowth
1258.0%10/10

Earnings expanding 1258.0% YoY

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

MRVL4 strengths · Avg: 9.0/10
Market CapQuality
$264.11B10/10

Mega-cap, among the largest globally

Profit MarginProfitability
29.0%9/10

Keeps 29 of every $100 in revenue as profit

Debt/EquityHealth
0.299/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
27.6%8/10

Revenue surging 27.6% year-over-year

Areas to Watch

MDLN4 concerns · Avg: 3.5/10
P/E RatioValuation
31.4x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.794/10

Distress zone — elevated risk

Profit MarginProfitability
3.3%3/10

3.3% margin — thin

Debt/EquityHealth
1.123/10

Elevated debt levels

MRVL4 concerns · Avg: 3.5/10
PEG RatioValuation
1.644/10

Expensive relative to growth rate

Price/BookValuation
18.7x4/10

Trading at 18.7x book value

Altman Z-ScoreHealth
1.904/10

Grey zone — moderate risk

P/E RatioValuation
104.0x2/10

Premium valuation, high expectations priced in

Comparative Analysis Report

WallStSmart Research

Bull Case : MDLN

The strongest argument for MDLN centers on EPS Growth, Price/Book. Revenue growth of 10.7% demonstrates continued momentum.

Bull Case : MRVL

The strongest argument for MRVL centers on Market Cap, Profit Margin, Debt/Equity. Profitability is solid with margins at 29.0% and operating margin at 14.5%. Revenue growth of 27.6% demonstrates continued momentum.

Bear Case : MDLN

The primary concerns for MDLN are P/E Ratio, Altman Z-Score, Profit Margin. Thin 3.3% margins leave little buffer for downturns.

Bear Case : MRVL

The primary concerns for MRVL are PEG Ratio, Price/Book, Altman Z-Score. A P/E of 104.0x leaves little room for execution misses.

Key Dynamics to Monitor

MDLN profiles as a value stock while MRVL is a growth play — different risk/reward profiles.

MRVL is growing revenue faster at 27.6% — sustainability is the question.

MRVL generates stronger free cash flow (483M), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MDLN scores higher overall (55/100 vs 55/100) and 10.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medline Inc. Class A Common Stock

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. The company is headquartered in Northfield, Illinois.

Visit Website →

Marvell Technology Group Ltd

TECHNOLOGY · SEMICONDUCTORS · USA

Marvell Technology, Inc. designs, develops, and sells analog, mixed-signal, digital signal processing, and integrated and independent integrated circuits. The company is headquartered in Wilmington, Delaware.

Visit Website →

Want to dig deeper into these stocks?